Literature DB >> 28794139

Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality.

James A Fallavollita1, Jonathan D Dare2, Randolph L Carter2, Sunil Baldwa2, John M Canty2.   

Abstract

BACKGROUND: Previous studies have identified multiple risk factors that are associated with total cardiac mortality. Nevertheless, identifying specific factors that distinguish patients at risk of arrhythmic death versus heart failure could better target patients likely to benefit from implantable cardiac defibrillators, which have no impact on nonsudden cardiac death. METHODS AND
RESULTS: We performed a pilot competing risks analysis of the National Institutes of Health-sponsored PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography). Death from cardiac causes was ascertained in subjects with ischemic cardiomyopathy (n=204) eligible for an implantable cardiac defibrillator for the primary prevention of sudden cardiac arrest after baseline clinical evaluation and imaging at enrollment (positron emission tomography and 2-dimensional echo). Mean age was 67±11 years with an ejection fraction of 27±9%, and 90% were men. During 4.1 years of follow-up, there were 33 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator discharge for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardiac deaths. Sudden cardiac arrest was correlated with a greater volume of denervated myocardium (defect of the positron emission tomography norepinephrine analog 11C-hydroxyephedrine), lack of angiotensin inhibition therapy, elevated B-type natriuretic peptide, and larger left ventricular end-diastolic volume index. In contrast, nonsudden cardiac death was associated with a higher resting heart rate, older age, elevated creatinine, larger left atrial volume index, and larger left ventricular end-diastolic volume index.
CONCLUSIONS: Distinct clinical, laboratory, and imaging variables are associated with cause-specific cardiac mortality in primary-prevention candidates with ischemic cardiomyopathy. If prospectively validated, these multivariable associations may help target specific therapies to those at the greatest risk of sudden and nonsudden cardiac death. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT01400334.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  coronary artery disease; death, sudden, cardiac; defibrillators, implantable; heart failure; positron-emission tomography; risk factors

Mesh:

Year:  2017        PMID: 28794139      PMCID: PMC5555076          DOI: 10.1161/CIRCIMAGING.117.006446

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  27 in total

1.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

2.  Mode of death in heart failure: findings from the ATLAS trial.

Authors:  P A Poole-Wilson; B F Uretsky; K Thygesen; J G F Cleland; B M Massie; L Rydén
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

3.  Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality.

Authors:  Andrew T Yan; Adolphe J Shayne; Kenneth A Brown; Sandeep N Gupta; Carmen W Chan; Tuan M Luu; Marcelo F Di Carli; H Glenn Reynolds; William G Stevenson; Raymond Y Kwong
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

4.  High-risk electrocardiographic parameters are ubiquitous in patients with ischemic cardiomyopathy.

Authors:  Mary G Carey; Salah S Al-Zaiti; John M Canty; James A Fallavollita
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

5.  Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.

Authors:  Eric S Williams; Svati H Shah; Jonathan P Piccini; Albert Y Sun; Jason I Koontz; Sana M Al-Khatib; Patrick M Hranitzky
Journal:  Europace       Date:  2011-08-06       Impact factor: 5.214

6.  Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease.

Authors:  David Bello; Arnold Einhorn; Rishi Kaushal; Satish Kenchaiah; Aidan Raney; David Fieno; Jagat Narula; Jeffrey Goldberger; Kalyanam Shivkumar; Haris Subacius; Alan Kadish
Journal:  Magn Reson Imaging       Date:  2010-10-25       Impact factor: 2.546

7.  Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation.

Authors:  L Brent Mitchell; Edgar A Pineda; Jack L Titus; Paulette M Bartosch; David G Benditt
Journal:  J Am Coll Cardiol       Date:  2002-04-17       Impact factor: 24.094

8.  Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Authors:  Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

9.  Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function.

Authors:  Rob S B Beanlands; Terrence D Ruddy; Robert A deKemp; Robert M Iwanochko; Geoffrey Coates; Michael Freeman; Claude Nahmias; Paul Hendry; Robert J Burns; Andre Lamy; Lynda Mickleborough; William Kostuk; Ernest Fallen; Graham Nichol
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094

10.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.

Authors:  Alfred E Buxton; Kerry L Lee; Gail E Hafley; Luis A Pires; John D Fisher; Michael R Gold; Mark E Josephson; Michael H Lehmann; Eric N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

View more
  17 in total

Review 1.  New Concepts in Sudden Cardiac Arrest to Address an Intractable Epidemic: JACC State-of-the-Art Review.

Authors:  Sanjiv M Narayan; Paul J Wang; James P Daubert
Journal:  J Am Coll Cardiol       Date:  2019-01-08       Impact factor: 24.094

2.  First-in-Human Studies of [18F] Fluorohydroxyphenethylguanidines.

Authors:  David M Raffel; Yong-Woon Jung; Robert A Koeppe; Keun Sam Jang; Guie Gu; Peter J H Scott; Venkatesh L Murthy; Jill Rothley; Kirk A Frey
Journal:  Circ Cardiovasc Imaging       Date:  2018-12       Impact factor: 7.792

Review 3.  Structural and Physiological Imaging to Predict the Risk of Lethal Ventricular Arrhythmias and Sudden Death.

Authors:  Saurabh Malhotra; John M Canty
Journal:  JACC Cardiovasc Imaging       Date:  2019-10

4.  American perspective: Comparing the AHA/ACC and ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

Authors:  Saurabh Malhotra; John M Canty
Journal:  J Nucl Cardiol       Date:  2017-08-22       Impact factor: 5.952

5.  Risk Stratification and Sudden Cardiac Death: Is It Time to Include Autonomic Variables?

Authors:  Houman Khakpour; Marmar Vaseghi
Journal:  Circ Cardiovasc Imaging       Date:  2017-08       Impact factor: 7.792

6.  Importance of individual patient characteristics when assessing the ability of cardiac adrenergic imaging to guide ICD use.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2020-10-20       Impact factor: 5.952

7.  Editorial commentary: Is it still important to evaluate patients with ischemic cardiomyopathy for viable dysfunctional myocardium prior to myocardial revascularization?

Authors:  John M Canty
Journal:  Trends Cardiovasc Med       Date:  2017-08-19       Impact factor: 6.677

8.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

9.  Reproducible Quantification of Regional Sympathetic Denervation with [11C]meta-Hydroxyephedrine PET Imaging.

Authors:  Jean Z Wang; Jonathan B Moody; Nicole Kaps; Deron Britt; Aaryn Lavallee; Jennifer M Renaud; Jason G E Zelt; Kai Yi Wu; Rob S Beanlands; James A Fallavollita; John M Canty; Robert A deKemp
Journal:  J Nucl Cardiol       Date:  2020-04-28       Impact factor: 5.952

10.  Does quantification of [11C]meta-hydroxyephedrine and [13N]ammonia kinetics improve risk stratification in ischemic cardiomyopathy.

Authors:  Jean Z Wang; Jason G E Zelt; Nicole Kaps; Aaryn Lavallee; Jennifer M Renaud; Benjamin Rotstein; Rob S B Beanlands; James A Fallavollita; John M Canty; Robert A deKemp
Journal:  J Nucl Cardiol       Date:  2021-08-02       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.